Driving Laws and Prescribed Cannabis: Tasmania

The question Tasmanian patients ask most

Forty-three kilometres from Hobart on the Huon Highway, there's a stretch of road that cuts through apple country with almost no margin for error on either side. It's a fair picture of where patients with prescribed cannabis sit under Tasmanian law. I've been through the Tasmanian Road Safety (Alcohol and Drugs) Act 1970 closely, trying to work out exactly what it says, and doesn't say, about prescribed cannabis and roadside testing. The short version is that it's genuinely complicated, and the answer changed as recently as 2024.

For patients who hold a valid Australian prescription for a cannabis-based medicine, the regulatory situation in Tasmania sits at the intersection of federal scheduling law, state traffic law, and the blunt reality of how roadside drug tests actually work. Those three things do not always point in the same direction.

This article is general education about how the framework is built. It is not legal advice, and it does not tell anyone what to do. If you want the wider access picture first, our regulatory overview of medicinal cannabis access in Tasmania covers the prescribing side.

How prescribed cannabis sits under federal law first

Before the state-level rules make sense, the federal layer matters. Cannabis medicines in Australia are accessed primarily through two pathways: the TGA's Special Access Scheme (Category B, the most common route for individuals) or via an Authorised Prescriber arrangement, where a doctor has TGA approval to prescribe to a class of patients without a per-patient application. Both are explained in more detail in our pieces on the Special Access Scheme and the Authorised Prescriber Scheme.

Most prescribed cannabis products containing tetrahydrocannabinol (THC) are classified as Schedule 8 controlled drugs under the Poisons Standard. Products containing only cannabidiol with no measurable THC can sit at Schedule 4 (prescription only). That distinction between THC-containing and THC-free formulations is central to understanding driving law, because roadside oral fluid tests do not test for CBD. They test for THC.

It helps to be clear about what scheduling does and doesn't do. A schedule is a federal classification that controls how a substance is supplied and prescribed. It says nothing about whether a person may drive after taking it. Driving is regulated by each state and territory, which is why a lawful prescription under federal arrangements and a positive roadside result under state traffic law can exist side by side. If that division of responsibility is new to you, state versus federal drug regulation in Australia sets it out, and the Poisons Standard explained covers how the schedules themselves work.

What Tasmania's road laws actually say

Tasmania operates under the Road Safety (Alcohol and Drugs) Act 1970 (Tas), amended over the years to add drug driving provisions. The offence framework has two separate limbs, and this is where patients sometimes get confused.

The first limb is a presence-based offence: it is an offence to drive with a prescribed illicit drug, including THC, present in your oral fluid, blood, or urine. This is the offence that catches people regardless of impairment. Critically, the law does not include an exemption for patients who hold a valid prescription. A positive roadside test for THC is, on the face of the Act, an offence, even if the THC in your system came from a medicine you were lawfully prescribed.

The second limb is an impairment-based offence: driving whilst impaired by a drug. This one applies regardless of whether the drug is prescribed, illicit, or over-the-counter.

The two limbs exist for different reasons. Presence offences are designed to be simple to enforce: a device returns a result and the question of how impaired the driver felt never arises. Impairment offences require evidence about how a person was actually driving or behaving. Patients get tripped up by assuming that "I wasn't impaired" answers both. It answers only the second.

Tasmania has historically been one of the stricter states on the prescription exemption question. Unlike some jurisdictions that have moved to provide a statutory defence or exemption for prescribed cannabis patients on the presence-based offence, Tasmania's framework as of mid-2025 does not contain a blanket prescription exemption of that kind. The Tasmanian government has flagged reform in this space, but as of the date of publication, patients should not assume a valid prescription protects them from the roadside presence-based offence.

I'll be direct: I think this is an unsatisfactory position. A person who has used a prescribed Schedule 4 CBD-dominant product that happens to contain trace THC, well within lawful prescribing, can still return a positive oral fluid test days after their last dose, long after any pharmacological effect has passed. The law in its current form doesn't distinguish between that scenario and someone who smoked cannabis recreationally the night before. That's a real problem for patients.

How roadside drug testing works in Tasmania

Tasmania Police conduct roadside oral fluid testing using approved devices. The test detects the presence of THC (among other drugs). It does not measure a concentration; it gives a positive or negative result. If the preliminary test is positive, a second oral fluid sample is collected, and a blood sample may also be taken for laboratory analysis.

That positive-or-negative design is worth understanding. A screening device is built to answer one narrow question, whether the substance is detectable above a set threshold, quickly and at the kerbside. It cannot tell an officer when the person last took a medicine, how much they took, or whether they were affected. Those questions only come into play later, if at all, through laboratory analysis and the surrounding evidence.

The detection window for THC in oral fluid is generally shorter than in urine, broadly hours to a day or two for most people after moderate use; but this varies depending on the frequency of use, the formulation, and individual pharmacokinetics. Pharmacokinetics simply means how a substance is absorbed, distributed, broken down and cleared by the body, and it differs between people. Patients using oil-based formulations, which affect absorption and clearance differently, should be aware that no reliable personal test can replicate what an approved device will return at the roadside. For more on how those formulations behave in general, see how oral oils and capsules work.

Prescription exemptions and the impairment offence

A number of Australian states have introduced or proposed some form of prescription-based defence or exemption for the presence offence. Queensland, for instance, amended its traffic legislation to provide a defence for patients with a valid prescription, subject to conditions. Western Australia proposed similar changes. The ACT has its own framework. Each jurisdiction has landed somewhere different, so it's worth reading the state pages directly, such as our notes on driving laws in Queensland, driving laws in Western Australia and driving laws in the Australian Capital Territory.

Tasmania has not enacted an equivalent exemption as of mid-2025. The Tasmanian government's Department of State Growth (which oversees road safety policy) and Tasmania Police have both acknowledged the policy tension here, but legislative amendment had not been passed at the time of writing. This is an active area of law reform nationally, and the position will change. Patients and prescribers should check current legislation directly with Service Tasmania or consult a Tasmanian traffic lawyer for up-to-date advice.

What this means practically: a Tasmanian patient prescribed a THC-containing Schedule 8 medicine should understand they are currently not protected from a presence-based drug driving offence by virtue of holding that prescription. Whether prosecution would proceed is a separate matter, because prosecutorial discretion exists; but the legal exposure is real.

Even if Tasmania were to introduce a prescription exemption for the presence offence (which I expect will happen eventually, given the national direction), the impairment offence would remain fully operative. No prescription anywhere in Australia exempts a driver from the obligation not to drive whilst impaired. That applies to cannabis, benzodiazepines, opioids, and any other prescribed medicine that carries sedative or psychoactive effects.

Prescribers are expected to counsel patients about this. TGA guidance, and the standard of care expected under the Authorised Prescriber framework, includes advising patients on driving. But the obligation ultimately rests with the driver.

CBD-only products and roadside testing

Patients using a Schedule 4 product where the formulation contains no THC, a true CBD isolate or a broad-spectrum product from which THC has been removed, face a different situation at the roadside. Standard oral fluid tests do not screen for CBD. A patient who is genuinely using a zero-THC product and returns a negative THC screen is not exposed to the presence offence on that basis.

The practical complication is that "zero THC" is not always a guarantee in every product. Full-spectrum cannabis oils, by definition, contain the full range of cannabinoids including THC, even at low concentrations. Patients should understand exactly what is in their prescription medicine. A full-spectrum oil prescribed for its broader cannabinoid profile will contain THC; a CBD isolate formulation will not.

The terminology trips people up, so it's worth spelling out. "Isolate" refers to a single purified compound. "Broad-spectrum" generally describes an extract that retains several cannabinoids with THC removed. "Full-spectrum" describes an extract that keeps the plant's wider cannabinoid range, THC included. Marketing language around these terms is loose, which is why the product's documented composition, as supplied with the prescription, is the thing to rely on rather than a label's wording. Any questions about a specific product belong with the prescriber or dispensing pharmacist.

What patients and prescribers should do now

Practically speaking, there are a few things worth understanding clearly.

• If you are a Tasmanian patient prescribed a THC-containing cannabis medicine, you should speak directly with your prescriber about driving and seek current legal advice if needed. Do not rely on advice that applied in another state.
• Prescribers operating under the SAS or as Authorised Prescribers are expected to document that they have counselled patients about driving. Check the TGA's published guidance on this.
• The law in this area is evolving. Tasmania's road safety legislation has been amended before and may be amended again. The authoritative source is the Tasmanian Legislation Online database and Tasmania Police's published policy.
• A valid prescription is currently not a statutory defence to the presence offence in Tasmania; but it may be relevant to prosecutorial decision-making and to any subsequent court proceeding.

One common mistake is treating advice from a friend, a forum or another state as if it applied in Tasmania. Another is assuming the rules that govern driving also govern work; they don't. Employers set their own testing policies, and those interact with prescribed medicines in a different way, which we cover in workplace drug testing and prescribed medicines.

Tasmania remains one of the more conservative jurisdictions on this question. That may change. But patients need to know where the law sits today, not where advocates hope it will sit tomorrow.

Sources

• Road Safety (Alcohol and Drugs) Act 1970, Tasmanian Legislation Online
• Prescribing Medicinal Cannabis; Therapeutic Goods Administration (TGA)
• Medicinal Cannabis Regulations, Australian Government Department of Health
• Cannabis Drug Facts, Alcohol and Drug Foundation (ADF)

Marcus Hale, Regulatory researcher; TGA & access law